Sequani invests in industry leading facilities as it eyes future growth
February 27, 2024 – Drug Discovery – CROs, Sequani, appointments, laboratory
26 February 2024 — Ledbury, UK — As part of their strategic plans for growth and to meet the evolving needs of modern product developers, Ledbury-based contract research organisation (CRO) Sequani has made a significant investment in a new custom designed facility incorporating 820m2 of laboratory space and a 910m2 modern vivarium, whilst also appointing Lee Coney as CSO.
With over 30 years’ of product development and senior managerial experience in the sector, Lee will take a leading role in working with the company’s customers to develop a wide range of pharmaceutical, crop protection and chemical products.
Speaking about the new facility, Lee said, “The new state-of-the-art lab and vivarium will enable us to be more flexible and allow us to support the evolving needs of our customers and worldwide regulatory authorities. Amongst other advantages, co-locating the laboratory and animal facilities into a single building offers enhanced biosecurity for sample flows from animal unit to analytical laboratory. It’s more efficient and will allow us to deliver a superior service.”
The new facility has flexibility at its core, allowing Sequani to work with a wider range of novel products. As the greater part of GLP non-clinical safety testing is performed in CROs, it is critical that laboratories adapt to the changing needs of their customers.
Commenting on the new facility and CSO appointment, Sequani CEO, Stephen Eckley said, “I am very proud of the decisions we have made as we look to the future. As a business we have always challenged ourselves to lead from the front. The advances we are making as we support our customers to protect human health bear testament to that.”
“Non-clinical safety assessment used to be a prescriptive business but that’s no longer the case. We work with a wide range of organisations in the pharmaceutical, crop protection and chemical industries. It’s vital that we keep abreast of developments in the field and understand how this impacts our customers.”
“Lee’s appointment comes at a pivotal time and, working with our highly experienced team of talented technologists and scientists, he will ensure that we continue to increase our capabilities, knowledge and experience across a wide range of analytical areas.”
Sequani is attending SOT in Salt Lake City from 10–14 March.
About Sequani
Sequani’s heritage spans more than 40 years when a company called Toxicol Laboratories opened for business in London before moving to the company’s current site in Bromyard Road, Ledbury. A little while later we went on to join IQVIA (Quintiles); a venture destined to grow into one of the largest contract research organisations in the world. Visit: www.sequani.com.
